dromlakhani Choose weight‑losing/neutral medications for T2DM overweight/obese
STEP 1 — Gather Information
Confirm T2DM diagnosis, assess BMI (overweight: BMI ≥ 27 kg/m² with comorbidity or obese: BMI ≥ 30 kg/m²), current glucose‑lowering regimen, HbA1c, weight, renal function, history of pancreatitis, medullary thyroid carcinoma/MEN2, genital mycotic infections, and any contraindications to GLP‑1 agonists or SGLT2 inhibitors. Proceed to evaluate contraindications.
STEP 2 — Rule In / Rule Out
Are there contraindications to GLP‑1 agonist or SGLT2 inhibitor use?
- No contraindications → go to Step 3.
- Yes (e.g., eGFR < 30 mL/min/1.73 m² for SGLT2i, personal/family history of medullary thyroid carcinoma for GLP‑1RA) → rule out those classes and consider only weight‑neutral options (metformin, DPP‑4 inhibitor); then go to Step 3.
STEP 3 — Classify or Stratify
If weight loss is a priority and no contraindications → classify as candidate for weight‑losing agents (GLP‑1 agonist or SGLT2 inhibitor).
If weight‑neutral therapy is acceptable or weight‑losing agents are contraindicated → classify as candidate for weight‑neutral agents (metformin ± DPP‑4 inhibitor). Select the appropriate medication class.
STEP 4 — Decide
- For weight‑losing priority: initiate a GLP‑1 agonist (e.g., liraglutide 0.6 mg SC daily, titrate to 1.8 mg) or an SGLT2 inhibitor (e.g., empagliflozin 10 mg daily) in addition to metformin.
- For weight‑neutral preference: continue metformin and add a DPP‑4 inhibitor (e.g., sitagliptin 100 mg daily) if further glycemic control is needed.
Prescribe the chosen agent, counsel on adverse effects, and schedule follow‑up in 4–6 weeks.
Clinical Guardrails / Mimics / Pitfalls
Avoid sulfonylureas, thiazolidinediones, and insulin monotherapy due to high weight‑gain risk. Do not use GLP‑1 agonists in patients with personal/family history of medullary thyroid carcinoma or MEN2, or with a history of pancreatitis. Avoid SGLT2 inhibitors in patients with eGFR < 30 mL/min/1.73 m², recurrent genital mycotic infections, or volume depletion. Monitor for hypoglycemia when combining insulin secretagogues or insulin with GLP‑1 agonists/SGLT2 inhibitors. Assess genital hygiene and advise on SGLT2 inhibitor‑associated infection risk.
Concrete Clinical Example
A 58‑year‑old man with T2DM, BMI 32 kg/m², HbA1c 8.0 % on metformin 1000 mg BID asks which medication will not worsen his weight. No contraindications to GLP‑1RA or SGLT2i; weight loss is desired. Decision: add liraglutide 0.6 mg SC daily, titrate to 1.8 mg, continue metformin, and re‑evaluate weight and HbA1c in 8 weeks.
Source: Section 2.1, page 4, Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, 2015, DOI:10.1210/jc.2014-3415